Evidence map›Paper›PMID 30093391›Full record

ArticleJournal of clinical microbiology2018

Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.

Hsuan-Chen Wang, Ming-I Hsieh, Pui-Ching Choi, Chi-Jung Wu

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Azole Resistance andJournal of fungi (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Distribution ofOpen forum infectious diseases · 2022
    Article
  16. Article
  17. Article
  18. Studies in mycology · 2021
    Review
  19. Article
  20. Can We Improve Antifungal Susceptibility Testing?Frontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hsuan-Chen WangNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
Ming-I HsiehNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
Pui-Ching ChoiNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
Chi-Jung WuNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan wucj@nhri.org.tw.
National Health Research Institutes · TWNational Cheng Kung University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study compared the YeastOne and reference CLSI M38-A2 broth microdilution methods for antifungal susceptibility testing of

Indexed as

Amphotericin BAntifungal AgentsAspergillosisAspergillusDrug ToleranceHumansItraconazoleMicrobial Sensitivity TestsReference StandardsSpecies SpecificityTriazolesVoriconazoleAmphotericin BAntifungal AgentsItraconazoleposaconazoleTriazolesVoriconazoleamphotericin Bantifungal susceptibilityAspergillusazolesCLSI M38-A2Sensititre YeastOneTR34/L98Htrailing growth

Identifiers

PMID30093391
PMCPMC6156308
OpenAlexW2887793580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.